Jul 2026· Journal of Translational Medicine· 0 citations
Medicine
TL;DR
This review examines NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functional shifts.
Abstract
The NLRP3 inflammasome is a central regulator of innate immunity and inflammation, but its functions extend beyond a simple pro-inflammatory role. Increasing evidence indicates that the biological consequences of NLRP3 activation are highly context-dependent, with protective or pathogenic effects determined by cellular composition, tissue microenvironment, and disease stage. In this review, we examine NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functional shifts. We further discuss three major determinants of NLRP3 output: cytokine bias between IL-1β and IL-18, cell-fate decisions between pyroptosis and survival, and epigenetic programming of inflammasome-responsive states. Using representative disease settings such as cancer, inflammatory bowel disease, and autoimmune disorders, we illustrate how similar NLRP3 activation can lead to divergent biological outcomes. We also discuss the therapeutic implications of this plasticity, arguing that effective intervention will require context-selective rather than universal inhibition. A more precise understanding of NLRP3 context dependence may support rational trial design, biomarker development, future patient-stratification frameworks, and more biologically informed therapeutic strategies in NLRP3-related diseases.
Although targeted modulation of inflammasome pathways represents a promising therapeutic strategy, further research is needed to refine patient selection, identify reliable biomarkers, and better characterise disease heterogeneity to enable successful clinical translation.
Caroline Neumann, Florian Hickl, Julia Kemnitzer et al.· Critical Care· 0 citations
Recent advances in the understanding of the molecular mechanisms that mediate interactions between NLRP3 and other inflammasome-associated pathways are summarized, focusing on shared signaling components, organelle dynamics, posttranslational modifications, and feedback regulatory circuits.
Nan-Yang Xiao, Ze-Xuan Lu, D. Cooper et al.· Cellular & Molecular Immunol...· 0 citations
A comprehensive overview of multi-level therapeutic strategies directed against the NLRP3 inflammasome is provided, critically evaluates preclinical and clinical evidence—including findings from the CANTOS trial—and discusses the translational potential of NLRP3-targeted immunometabolic therapy in CVDs.
Tian-Qing Zhang, Li Luo, Kai-Lin Yang et al.· Frontiers in Immunology· 1 citation
It is proposed that future NLRP3-targeted therapy for osteomyelitis should shift from “non-specific anti-inflammation” to “bone immune reprogramming”—stratified intervention based on infection stage, cell type, and inflammasome activation level, integrating NLRP3 modulation with antibacterial, anti-biofilm, anti-pyropt...
Li-Dan Yang, Lin Zhang, Xu-Xu Yang et al.· Frontiers in Immunology· 0 citations
The molecular mechanisms underlying NLRP3 inflammasome activation in liver diseases are summarized, its contribution to hepatic inflammation and fibrosis is discussed, and emerging therapeutic strategies targeting this pathway are explored.
Kunj Ghantiwala, Ruchik Kevadiya, A. Thakor et al.· International Journal For Mu...· 0 citations
This study signifies the mechanisms underlying circadian regulation of the P2X7–NLRP3 axis, its tissue-specific roles in obesity, and available preclinical and clinical evidence, and further review innovative therapeutics like inflammatory inhibiting targets including inflammasome inhibitors, P2X7 antagonists and chron...